ReviewAdvances in anatomic pathology2017
What is New in Gastrointestinal Stromal Tumor?
Review in Advances in anatomic pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 108 citations in OpenAlex.
- Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Precision therapeutic strategies for advanced gastrointestinal stromal tumors.Cancer metastasis reviews · 2026Review
- Non-Coding RNAs in Gastrointestinal Stromal Tumors: Regulatory Networks, Drug Resistance, and Clinical Implications.International journal of molecular sciences · 2026Review
- The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics.Frontiers in oncology · 2026Review
- Comparative Evaluation of Endoscopic Ultrasonography and Multi-Slice Spiral CT in Diagnosing Gastrointestinal Stromal Tumors: A Retrospective Study.International journal of general medicine · 2026Article
- Whipple procedure for duodenal gastrointestinal stromal tumors: A report of two cases.International journal of surgery case reports · 2025Article
- Postoperative perforation risk after endoscopic removal of gastric gastrointestinal stromal tumors: Development and validation of a predictive nomogram.World journal of gastrointestinal endoscopy · 2025Article
- Nuclear Pleomorphism in Gastrointestinal Stromal Tumors: Insights Beyond Risk Stratification.Cureus · 2025Article
- Long-term outcomes of endoscopic treatment versus surgical resection for 0-2 cm gastrointestinal stromal tumor: A SEER database study.Surgical endoscopy · 2025Article
- Gastrointestinal stromal tumors: Clinicopathological features and outcome-Real-world experience.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2025Article
- Anti-LGI1-antibody autoimmune encephalitis as a neurological paraneoplastic syndrome associated with gastrointestinal stromal tumour: a case report.Postepy psychiatrii neurologii · 2025Article
- Penile metastasis from a duodenal gastrointestinal stromal tumor: A rare case report.Urology case reports · 2025Article
- Genome-Wide DNA Methylation and Copy Number Alterations in Gastrointestinal Stromal Tumors.Genes, chromosomes & cancer · 2025Article
- Soft tissue sarcomas at the single-cell and spatial resolution: new markers and targets.Cancer gene therapy · 2025Review
- Case Report: Renal metastasis of a gastric gastrointestinal stromal tumor mimicking a primary renal carcinoma.Frontiers in oncology · 2025Article
- Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research.Global medical genetics · 2024Review
- Managing locally advanced GIST complicated by perforation: A case report and comprehensive review.Radiology case reports · 2024Article
- Article
- Gastrointestinal Stromal Tumors: A Retrospective Study at a Tertiary Care Center in Saudi Arabia in the Last Decade.Cureus · 2024Article
- KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST.Cell communication and signaling : CCS · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The classification "gastrointestinal stromal tumor" (GIST) became commonplace in the 1990s and since that time various advances have characterized the GIST lineage of origin, tyrosine kinase mutations, and mechanisms of response and resistance to targeted therapies. In addition to tyrosine kinase mutations and their constitutive activation of downstream signaling pathways, GISTs acquire a sequence of chromosomal aberrations. These include deletions of chromosomes 14q, 22q, 1p, and 15q, which harbor putative tumor suppressor genes required for stepwise progression from microscopic, preclinical forms of GIST (microGIST) to clinically relevant tumors with malignant potential. Recent advances extend our understanding of GIST biology beyond that of the oncogenic KIT/PDGFRA tyrosine kinases and beyond mechanisms of KIT/PDGFRA-inhibitor treatment response and resistance. These advances have characterized ETV1 as an essential interstitial cell of Cajal-GIST transcription factor in oncogenic KIT signaling pathways, and have characterized the biologically distinct subgroup of succinate dehydrogenase deficient GIST, which are particularly common in young adults. Also, recent discoveries of MAX and dystrophin genomic inactivation have expanded our understanding of GIST development and progression, showing that MAX inactivation is an early event fostering cell cycle activity, whereas dystrophin inactivation promotes invasion and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.